Today: 29 April 2026
Browse Category

Biotechnology 6 January 2026 - 12 January 2026

CRISPR Therapeutics stock (CRSP) drops into JPM week — what to watch next

CRISPR Therapeutics stock (CRSP) drops into JPM week — what to watch next

CRISPR Therapeutics shares fell 4.5% to $53.84 Friday ahead of its Monday presentation at the J.P. Morgan Healthcare Conference. Investors are focused on updates for Casgevy’s commercial rollout, patient starts, and payer coverage. The therapy, approved for sickle cell disease, is co-developed with Vertex, which records product revenue. Traders await signals on 2026 projections and revenue ramp-up.
12 January 2026
··
Regencell Bioscience (RGC) stock swings 45% then closes up 10.6% — what to watch Monday

Regencell Bioscience (RGC) stock swings 45% then closes up 10.6% — what to watch Monday

Regencell Bioscience shares closed Friday up 10.6% at $45.79 after swinging between $35.13 and $50.92 on heavy volume. The company disclosed a DOJ subpoena and warned of possible legal penalties and funding risks in its Oct. 31 annual report. Its auditor expressed “substantial doubt” about Regencell’s ability to continue as a going concern. No new corporate updates have been posted since the annual filing.
11 January 2026
··
Wave Life Sciences stock drops 7% into JPM Healthcare Conference week — what to know next

Wave Life Sciences stock drops 7% into JPM Healthcare Conference week — what to know next

Wave Life Sciences shares fell 6.7% to $13.84 Friday, underperforming biotech peers ahead of the J.P. Morgan Healthcare Conference. Investors are watching for CEO Paul Bolno’s Tuesday update on WVE-007, its obesity drug, after December’s interim data showed a 9.4% visceral fat reduction. The company recently raised $350 million in a public offering.
11 January 2026
··
CG Oncology stock jumps 29% on faster Phase 3 PIVOT-006 data clock — what to watch next

CG Oncology stock jumps 29% on faster Phase 3 PIVOT-006 data clock — what to watch next

CG Oncology shares jumped nearly 29% Friday, closing at $54.20, after the company said topline Phase 3 trial data for its bladder cancer therapy will arrive in the first half of 2026, almost a year early. Morgan Stanley raised its price target to $93, citing the accelerated timeline. The PIVOT-006 trial enrolled over 360 patients at more than 90 sites.
11 January 2026
··
Lilly’s TuneLab AI drug platform lands in Schrödinger LiveDesign as biotech access broadens

Lilly’s TuneLab AI drug platform lands in Schrödinger LiveDesign as biotech access broadens

Schrödinger will integrate Eli Lilly’s AI drug discovery platform, TuneLab, into its LiveDesign software, giving biotech teams direct access to Lilly’s predictive models. Revvity and Benchling also announced deals to offer TuneLab through their platforms. Lilly and Revvity will jointly fund access for select users, using federated learning to protect data. BigHat Biosciences will collaborate with Lilly to improve antibody developability models.
10 January 2026
····
CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics shares fell 4.3% to $54.00 after a filing showed CFO Raju Prasad exercised and sold 29,700 shares under a preset trading plan. The move comes ahead of the company’s Jan. 12 slot at the J.P. Morgan Healthcare Conference and an expected mid-February earnings report. Gene-editing peers also traded lower. CASGEVY revenue and rollout remain key investor focus.
9 January 2026
·······
CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026

CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026

CG Oncology shares surged 25.1% to $52.45 after the company advanced the expected release of late-stage bladder cancer trial results to the first half of 2026. The PIVOT-006 Phase 3 trial enrolled over 360 patients and compares cretostimogene grenadenorepvec to surveillance after tumor removal. Trading volume topped 4.1 million shares by midday. Morgan Stanley raised its price target on the stock to $89.
9 January 2026
···
Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck shares rose 1.5% to $110.20 after Wolfe Research upgraded the stock and set a $135 price target. Merck completed its $221.50-per-share tender offer for Cidara and flagged a $9 billion R&D charge for 2026. Investors watched fallout from a U.S. shift to a single-dose HPV vaccine recommendation ahead of Merck’s Feb. 3 results.
8 January 2026
····
Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update

Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update

Immuneering shares surged 24% to $8.33 premarket after reporting 64% overall 12-month survival in a 34-patient Phase 2a pancreatic cancer trial. The company compared this to a 35% benchmark from standard chemotherapy. Median progression-free survival reached 8.5 months. Immuneering plans a larger data update and to start a Phase 3 trial in mid-2026.
8 January 2026
···
Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

Amgen shares rose 3.5% to $341.64 after UBS initiated coverage with a buy rating and a $380 target. The move follows FDA approval of Amneal’s biosimilar rivals to Amgen’s Prolia and Xgeva, which generated $5.3 billion in U.S. sales last year. Amgen also announced an $840 million deal to acquire Dark Blue Therapeutics, adding an early-stage leukemia drug. CEO Robert Bradway will present at the J.P. Morgan Healthcare Conference on Jan. 12.
8 January 2026
···
Adaptive Biotechnologies (ADPT) stock jumps as biotech gains; SEC filing flags insider sale

Adaptive Biotechnologies (ADPT) stock jumps as biotech gains; SEC filing flags insider sale

Adaptive Biotechnologies shares climbed 6.5% to $17.15 by midday Wednesday, outpacing broader market gains. Biotech ETFs rose about 2.5%. A Form 4 showed Chief People Officer Francis Lo sold 3,125 shares on Jan. 2 under a prearranged 10b5-1 plan, after exercising options. The company is set to present at the J.P. Morgan Healthcare Conference on Jan. 12.
7 January 2026
··
Structure Therapeutics stock climbs on $100 million Roche-Genentech patent deal; what investors watch next

Structure Therapeutics stock climbs on $100 million Roche-Genentech patent deal; what investors watch next

Structure Therapeutics shares rose 5.6% to $66.75 after an SEC filing revealed a $100 million upfront payment and low single-digit royalties from Roche and Genentech for a patent license covering oral GLP-1 drugs, including CT-996. The agreement does not affect Structure’s lead candidate, aleniglipron. Full contract details will be disclosed in the annual report.
7 January 2026
·
Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Bayer’s Monsanto filed a lawsuit against Pfizer, BioNTech, and Moderna in Delaware federal court, alleging misuse of mRNA technology patents. Pfizer shares rose 0.9% to $25.67 in early trading after UBS began coverage with a Neutral rating and a $25 price target. Investors are watching for Pfizer’s Q4 and full-year 2025 results on February 3.
7 January 2026
····
Regencell Bioscience (RGC) stock jumps again: what to know behind the latest sharp swing

Regencell Bioscience (RGC) stock jumps again: what to know behind the latest sharp swing

Regencell Bioscience Holdings shares jumped 18.3% to $31.99 in midday Nasdaq trading Tuesday, after swinging between $26.60 and $34.40. No new company statements have been posted since its Oct. 31 annual report, which disclosed a DOJ trading probe and “substantial doubt” about its ability to continue as a going concern. About 850,000 shares changed hands.
6 January 2026
··
1 … 3 4 5 6 7 … 16

Stock Market Today

  • Micron Technology Stock Outlook to 2030 Amid Soaring AI Memory Demand
    April 28, 2026, 9:37 PM EDT. Micron Technology (MU) has surged 522% in the past year, driven by booming demand for memory chips crucial for AI data centers. The company produces DRAM and NAND flash memory, essential for AI processors handling complex workloads. Industry forecasts suggest a persistent supply shortage through 2030, with data centers expected to consume 70% of global memory production this year. This tight supply-demand balance, supported by limited new factory capacity, positions Micron for sustained growth. Analysts anticipate continued earnings expansion, with fiscal 2025 EPS at $8.29 and potential dips in 2028 viewed as unlikely. Micron's strong footing in the red-hot AI memory market could enable further stock gains by the decade's end.

Latest article

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

29 April 2026
Oracle shares fell 4% and CoreWeave dropped 5.9% Tuesday after a Wall Street Journal report said OpenAI missed recent revenue and user targets. Nvidia, AMD, and Arm Holdings also declined, with the iShares Semiconductor ETF down 3.7%. OpenAI denied internal divisions and said its AI coding product Codex reached 4 million users. Oracle’s credit default swaps hit a two-week high amid concern over its $300 billion cloud deal with OpenAI.
Go toTop